MedTrace Logo

Alzheimer's Disease: Therapeutic Potential of Estrogen

NCT00066157 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2018-08-23

No results posted yet for this study

Summary

This is a 15-month study to determine the effectiveness of hormone replacement therapy in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.

Conditions

  • Alzheimer Disease

Interventions

DRUG

Transdermal estradiol

50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months

DRUG

Medroxyprogesterone

2.5mg tablet daily for 12 months

DRUG

Placebo Patch

Transdermal placebo patch, changed every 3 days, for 12 months

DRUG

Placebo

Placebo tablet daily for 12 months

Sponsors & Collaborators

  • National Institute on Aging (NIA)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Sanjay Asthana, MD · University of Wisconsin - Madison, William S. Middleton VA Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
90 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00066157 on ClinicalTrials.gov